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Abstract
Background: Addison’s disease (AD) is caused by an autoimmune destruction of the adrenal cortex. The
pathogenesis is multi-factorial, involving genetic components and hitherto unknown environmental factors. The
aim of the present study was to investigate if gene dosage in the form of copy number variation (CNV) could add
to the repertoire of genetic susceptibility to autoimmune AD.
Methods: A genome-wide study using the Affymetrix GeneChip
® Genome-Wide Human SNP Array 6.0 was
conducted in 26 patients with AD. CNVs in selected genes were further investigated in a larger material of patients
with autoimmune AD (n = 352) and healthy controls (n = 353) by duplex Taqman real-time polymerase chain
reaction assays.
Results: We found that low copy number of UGT2B28 was significantly more frequent in AD patients compared to
controls; conversely high copy number of ADAM3A was associated with AD.
Conclusions: We have identified two novel CNV associations to ADAM3A and UGT2B28 in AD. The mechanism by
which this susceptibility is conferred is at present unclear, but may involve steroid inactivation (UGT2B28) and T cell
maturation (ADAM3A). Characterization of these proteins may unravel novel information on the pathogenesis of
autoimmunity.
Background
Primary adrenal insufficiency (Addison’s disease (AD)) is
most commonly caused by an autoimmune destruction
of the adrenal cortex, resulting in failure to produce cor-
ticosteroids. AD can appear alone, but is frequently part
of autoimmune polyendocrine syndromes (APS). APS
type I is caused by mutations in the gene autoimmune
regulator (AIRE), which has a function in developing
immunological tolerance in the thymus (for review see
[1]). Isolated AD, or AD in combination with other
endocrine components where APS I has been ruled out,
is thought to be caused by a combination of genetic and
environmental factors, and stochastic events.
Using the candidate gene approach, several genes have
been associated with autoimmune AD. The human leu-
kocyte antigen (HLA) haplotypes DR3-DQ2 and DR4-
DQ8 is the strongest predisposing genetic factors [2,3].
Other susceptibility genes are MHC-class I related chain
A and B (MICA and MICB) [4,5], cytotoxic T lymphocyte
antigen-4 (CTLA-4) [6], tyrosine-protein phosphatase
non-receptor type 22 (PTPN22) [7], the gene encoding
MHC class II transactivator (CIITA) [8], C-type lectin
domain family 16, member A (CLEC16A)[ 9 ] ,Pro-
grammed death ligand 1 (PD-L1) [10], and the gene
coding for NACHT leucine rich repeats protein 1
(NALP1) [11]. All these genes are also associated with
other autoimmune diseases and can be viewed as auto-
immunity genes. So far a disease-specific AD gene has
not been identified, with the possible exception of the
DRB1*0404 HLA-subtype [2].
The recent identification of common copy number
variation (CNV) in the human genome as a source of
genetic modification could possibly explain some of the
susceptibility to autoimmunity. In support of this notion
is the finding that low copy number of FCGR3B (Fc
fragment of IgG, low affinity IIIb, receptor (CD16b)),
has been coupled to the systemic autoimmune diseases
systemic lupus erythematosus (SLE), vasculitis, micro-
scopic polyangiitis and Wegener’sg r a n u l o m a t o s i s[ 1 2 ] .
Low FCGR3B copy number possibly contributes to
impaired clearance of immune complexes, which is of
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specific diseases like Graves’ disease and AD, on the
other hand, fail to show this association [12]. A similar
gene, FCGR2C, is associated with idiopathic thrombocy-
topenic purpura [13]. Furthermore, low copy number of
the complement associated genes C4A and C4B have
been described in SLE-patients (reviewed in [14]).
Finally, aberrant copy number of the gene chemokine
ligand 3-like 1 (CCL3L1), a potent binder of several pro-
inflammatory cytokine receptors, has been reported in
SLE [15], while high copy number has been reported in
rheumatoid arthritis and type 1 diabetes [16].
These studies show that CNVs in immunoregulatory
genes could add to the susceptibility to autoimmune dis-
eases, and that identification of such genes can contri-
bute to the understanding of pathogenesis. Only a few
reports on genome-wide CNV have been reported in
organ-specific autoimmune diseases so far [17]. Here,
we have conducted the first genome-wide (GW) CNV
study in autoimmune AD.
Methods
Subjects
A total of 352 patients with autoimmune AD (63%
females, 37% males; mean age 57 years, range 13 - 93
years; 52% of whom had APS type II) recruited from the
National Norwegian Registry of patients with AD [2],
and 353 blood donors (35% females, 65% males, mean
age 46 years, range 19 - 71 years) were available for
CNV analyses. For comparison we had access to an in-
house database with CNV-results from 361 non-Addi-
son’s patients analysed with the same GW array. These
samples comprise individuals which were analysed for
CNVs in the daily routine analyses at the Medical
Genetics Department, Haukeland University Hospital,
for a diversity of dysfunctions. An overview of the sub-
jects used in the present study is given in Figure 1.
Ethical considerations
All included patients and blood donors signed a written
consent form. The study was approved by the Regional
Committee for Medical Ethics of Western Norway, and
performed according to the Helsinki Declaration.
GW CNV gene chip analyses
Twenty eight unrelated patients with isolated autoim-
mune AD (39% females, 61% males, mean age 63 years,
ranging from 26 to 96 years) were randomly selected for
GW CNV analyses. The genome-wide copy number
screening was performed using the Affymetrix Gene-
Chip
® Genome-Wide Human SNP Array 6.0, Part#
901182, (Affy 6.0) following the procedure described in
Affymetrix
® Cytogenetics Copy Number User Guide.
The arrays were scanned by the Gene Chip Scanner
3000 7G, controlled by the AGCC software. The array
data were analyzed by the Affymetrix Genotyping Con-
sole™ version 3.0.1. The Contrast quality control (QC)
was set to higher than 0.4 and the Median Absolute
Pair wise Difference (MAPD) threshold was set to 0.30
or less for each sample. CNV analysis was performed by
comparing the files from the AD patients with a refer-
ence file of 44 healthy controls (anonymous material
used in the daily routine analyses at the Medical Genet-
ics Department, Haukeland University Hospital). CNV
were further evaluated in the Affymetrix
® Genotyping
Console Browser version 1.0.11 and the Affymetrix
Chromosome Analysis Suite version 1.0.1. The CNVs
were flagged using a cut off filter of minimum 20 mar-
kers per 100 Kbp segment. Flagged CNVs were checked
against the Database of Genomic Variants (DGV)
(http://projects.tcag.ca/variation/)©[18]. Findings that
varied from the reference file were compared with the
in-house database from 361 non-AD individuals. In
addition, a search for CNVs in candidate genes of Addi-
son’s disease was performed on the chip data without
using cut off filters (see Additional file 1).
Additional CNV assays
Individual CNV assays were performed by duplex Taqman
real-time PCR assays in order to confirm findings on new
candidates from the GW analysis in a larger patient and
blood donor material. In addition, an individual CN assay
Figure 1 Flow chart of the methods and subjects used in the
present study.
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Affy 6.0 chip. FCGR3B, KIAA1267 and ADAM3A copy
number assays were supplied from Applied Biosystems
(Assay ID: Hs04211858_cn, Hs03983160_cn, and
Hs03269461_cn, respectively). Copy number assay for
UGT2B28 was designed by Applied Biosystems based on
the gene’s sequence (ugt2b28_CCGJPAM). RNaseP (Taq-
Man copy number reference assay, part # 4403328) and
Desmoplakin (DSP) (adapted from Parajes et al, 2007) [19]
were used as reference genes. All primers and probes were
supplied from Applied Biosystems, and duplex real-time
PCR assays were performed according to the TaqMan
®
copy number assay protocol (Applied Biosystems). All
data was further analyzed using the 7300 System SDS soft-
ware version 2.3. The genes were quantified by calibration
curves for each gene. The reference genes are known to
occur in two copies in the genome. Hence, the copy num-
ber was determined by the relative relationship between
the quantity of the candidate gene and the reference gene.
Statistics
Fisher’s Exact test was applied for comparing the fre-
quencies of CNs of the different genes in AD patients
and controls, using the statistical work package PASW
Statistics 18. The data was considered to be significant
when P < 0.05.
Results
Quality control of the Affy 6.0 gene chips
Twenty-six of twenty-eight arrays in the patient group
and all controls (N = 44) were in accordance with
Affymetrix’ recommendations, with MAPD values ran-
ging from 0.194-0.299 and QC call rate ranging from
88.2-99.0%. Two patient arrays failed these quality cri-
teria and were excluded from further analyses.
Frequent CNVs associated with AD
The gene regions with most frequent CNVs in AD
patients are given in Table 1 all of which are reported as
normal CN polymorphisms in the DGV [18]. Except for
the DEFB cluster region, a number of genes within this
region were found to have CNV that differed significantly
from 361 in-house non-AD controls (Table 1). Low CN
of KIAA1267 (coding for an uncharacterised protein) and
UGT2B28 (encoding uridine diphosphate glucuronosyl-
transferase (UGT) 2 family, polypeptide B28), and high
CN of ADAM3A (encoding a disintegrin and metallopro-
teinase domain 3A), occurred more frequently (> 30%) in
AD patients. These were selected for replication studies
in the large Addison and control cohorts.
The Affy 6.0 gene chip experiment revealed that a
heterozygous deletion (CN = 1) in the UGT2B28 gene
occurred more often in the AD patients (30%) than in
the in-house reference material (10%). This association
was confirmed (25% vs 14% P = 0.0008) in the large
AD patient and blood donor materials using the gene
specific CN assay (Figure 2a). On the other hand, the
heterozygous deletion (CN = 1) in the KIAA1267 gene
f o u n dt ob em o r ef r e q u e n t l yi nA Dp a t i e n t s( 3 8 %v s
9% respectively, Table 1), was no longer significant
(55% vs 59%, P = 0.48) (Figure 2b) in the replication
study.
Table 1 Gene regions (≥ 100 Kbp) of the most frequent copy number (CN) variation in patients with Addison’s disease
detected by gene chip
Patient ID CN Chromosome Genes CN Frequency (%)
1 P-value
2
AD
n=2 6
Controls
n = 361
14, 17, 19, 20 1
3
≥ 4
1q21.1 FCGR1C 15.3
0
0
2.2
0.8
0.3
P = 0.012
22
10, 19, 20, 26
2, 3
0
1
3
4q13.2 UGT2B17 3.8
15.3
7.7
1.9
1.4
5.0
P = 0.0018
8, 9, 13, 14, 15, 19, 22, 26
0
1
4q13.2 UGT2B28 0
30.7
0.3
10
P = 0.01
11, 16, 21, 26
19, 22
2, 5, 9, 10, 12, 13, 15, 17, 20
0
3
≥ 4
8p11.23-11.22 ADAM3A 15.4
7.7
34.6
3.6
0.3
9.7
P = 3.3 × 10
-7
9, 14, 21, 23 1
3
8p23.1 DEFB cluster 15.3
0
5.8
2.2
P = 0.165
5, 8, 10, 13, 16, 19, 20, 22, 23, 24
12, 15, 26
1
3
≥ 4
17q21.31 KIAA1267 38.4
11.5
0
8.5
3.3
0.6
P = 3.3 × 10
-6
The exact size and localisation of the CNVs varied slightly between patients, but in every case encompassed the listed genes.
1CN frequency (%) is the percentage of the individuals with the given copy number.
2CN frequencies in patients with Addison’s disease (AD) were compared to
controls and P-values for significance were calculated by Fisher’s Exact test.
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were detected more frequently in AD patients compared
to the in-house reference database (42% vs 10% respec-
tively) by the Affy 6.0 gene chip analysis (Table 1). A
significant association (P = 0.0002) of CNVs, with
respect to CN = 3, was still evident in the replication
experiment on the larger cohort with duplex Taqman
real-time PCR assays (Figure 2c).
The differences in CNVs for UGT2B28 and ADAM3A
were still evident when patients with isolated AD and
APS II were analysed separately. With respect to sex, the
association to UGT2B28 was only significant for males (P
= 0.002), while the association to ADAM3A was signifi-
cant for both females (P = 0.004) and males (P = 0.004).
Rare CNV in AD patients detected by Affy 6.0
We also performed a GW scan for rare CNVs (Table 2).
T h e s eC N V sa r en o tl i s t e di nt h eD G V[ 1 8 ] ,n o r
detected in our in-house database. Eight novel CNV
gene regions were found in the AD patients, with the
longest segment consisting of a 700 Kbp heterozygote
deletion which was found in patient #23 on chromo-
some 7p14.3. This segment covers only one gene, BMP
binding endothelial regulator (BMPER), an inhibitor of
bone morphogenetic protein (BMP) function. Patient #3
had two large CNVs regions, one heterozygote deletion
of 103 Kbp in 5q23.1 covering the last third part of the
17-beta-hydroxysteroid dehydrogenase IV gene
(HSD17B4),a n das i n g l ec o p yg a i no f1 1 5K b pi n
14q13.2, covering the NFKBIA gene (nuclear factor of
kappa light polypeptide gene enhancer in B-cells inhibi-
tor, alpha). Patient #20 had two regions of single copy
gain, one in 3q21.3 (102 Kbp), and one in 8p21.1 (103
Kbp) covering the gene SCARA5 (Scavenger receptor
class A, member 5).
CNV in candidate genes of AD
A number of candidate autoimmune genes of which
some have been reported to have CNV associated with
autoimmunity (e.g. FCGR3B), were tested for association
t oA D .O ft h e s e ,o n l yC N V si nt h ec a n d i d a t eg e n e s
CCL3L1 and HLA-DRB5 were detected by the gene chip
(see Additional file 1). No significant differences in CNV
were found in the selected candidates, including
FCGR3B (see Additional file 2).
Discussion
The present study is the first effort to search for com-
mon CNVs as a source for genetic susceptibility in AD.
We found two novel CNVs associated with AD,
UGT2B28 and ADAM3A. Both have previously been
reported as regions with copy number polymorphisms
[18].
The enzyme UGT2B28 is expressed in liver and mam-
mary glands, and it might play a role in steroid inactiva-
tion [20]. In the present study we found an increased
f r e q u e n c yo fC N=1o ft h eg e n eUGT2B28 in our AD
cohort. It has previously been reported that this hetero-
zygote deletion occurs in 23% of healthy Caucasians,
and deletions in this gene region, which also includes
the UGT2B17 gene, are very common [21]. The connec-
tion to autoimmunity, if any, is at present not clear.
We also found an association with CNV and
ADAM3A in AD patients. Three different transcript var-
iants of ADAM3A (Entrez Gene; http://www.ncbi.nlm.
nih.gov/gene; Gene ID 1587) have been reported, and
the gene is embedded in a cluster of other genes in the
ADAM family [18]. Several proteins of the ADAM
family are believed to be involved in the inflammation
Figure 2 Copy number variations in genes associated with AD
by the Affy 6.0 chip. Copy number frequencies in Addison
patients and controls for the three genes associated with AD by the
Affy 6.0 chip (AD chip) and validated by duplex RT-qPCR. UGT2B28
(a), KIAA1267 (b), and ADAM3A (c). P-values for differences of copy
number variation between Addison patients (AD Taqman) and
healthy controls (HC Taqman) were calculated by Fishers’s Exact
test.
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in T cell maturation and development [22,23]. The func-
tion of ADAM3A has mainly been associated with
sperm-egg binding and fusion [24], but it has also been
linked to pro-inflammatory activity and survival of
macrophages [25]. Thus a role in autoimmunity and
immunological tolerance can be envisioned.
Recent evidence shows that common genetic variants do
not explain all genetic susceptibility to autoimmune dis-
eases. Rare variants in a number of genes, e.g. PTPN22,
have been shown to be associated with autoimmune dis-
e a s e ss u c ha sA D[ 7 ]a n dd i a b e t e s[ 2 6 - 2 8 ] .O n ec o u l d
hypothesize that rare CNV could play a role for AD sus-
ceptibility. Thus, as an alternative approach we looked for
rare or private CNVs. We found that one patient had a
single copy gain of the NFKBIA gene, previously shown to
be related to Crohn’s diseases [29] and multiple sclerosis
[30]. This gene produces an inhibitor of NFKB1,w h i c h
encodes the NFB subunit 1. Gene polymorphisms in
NFB have been associated with type 1 diabetes [31]. The
same patient also had a heterozygous deletion in the
HSD17B4 gene. Mutations and deletions in this gene have
been reported to cause D-bifunctional protein deficiency
(http://www.ncbi.nlm.nih.gov/omim ID 601860). High
copy number of the gene SCARA5 was also detected in
one patient. This gene might be of interest because of its
expression in murine thymus and adrenals, and its func-
tion in innate immune activities of epithelial cells [32].
When searching for CNVs in candidate gene regions,
we only detected aberrant CN in the CCL3L1 and HLA-
DRB5 genes in some of the AD patients, but not signifi-
cantly different from controls. CNVs of these two genes
have been also reported previously as normal variants
[18]. Moreover, we did not find any association between
CNVs in the FCGR3B gene and AD, which is in agree-
ment to the results of Fanciulli et al (2007) [12].
Conclusions
We have identified two novel CNV associations to
ADAM3A and UGT2B28 in AD. The mechanism by
which this susceptibility is conferred is at present
unclear, but may involve steroid inactivation (UGT2B28)
and T cell maturation (ADAM3A). Characterization of
these proteins may unravel novel information on the
pathogenesis of autoimmunity.
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